Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2013, Article ID 930354, 8 pages
http://dx.doi.org/10.1155/2013/930354
Research Article

Direct and Indirect Drug Design Approaches for the Development of Novel Tricyclic Antipsychotics: Potential 5-HT2A Antagonist

1Department of Pharmaceutical Chemistry, MVP’s College of Pharmacy, Gangapur Road, Nashik, Maharashtra 422002, India
2Department of Pharmaceutical Chemistry, Sinhgad Institute of Pharmaceutical Sciences, Kusgaon Budruk, Lonavala, Maharashtra 410401, India

Received 3 May 2013; Accepted 30 July 2013

Academic Editor: John Gebler

Copyright © 2013 Mahantesh Namdev Jadhav et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC, USA, 4th edition, 1994.
  2. J. van Os and S. Kapur, “Schizophrenia,” The Lancet, vol. 374, no. 9690, pp. 635–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. B. P. Murphy, Y.-C. Chung, T.-W. Park, and P. D. McGorry, “Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review,” Schizophrenia Research, vol. 88, no. 1–3, pp. 5–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. A. C. Anderson, “The process of structure-based drug design,” Chemistry & Biology, vol. 10, pp. 778–797, 2003. View at Google Scholar
  5. G. H. Loew, H. O. Villar, and I. Alkorta, “Strategies for indirect computer-aided drug design,” Pharmaceutical Research, vol. 10, no. 4, pp. 475–486, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. L. R. McMahon and K. A. Cunningham, “Antagonism of 5-hydroxytryptamine2A receptors attenuates the behavioral effects of cocaine in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 1, pp. 357–363, 2001. View at Google Scholar · View at Scopus
  7. P. J. Weiden, “EPS profiles: the atypical antipsychotics: are not all the same,” Journal of Psychiatric Practice, vol. 13, no. 1, pp. 13–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. C. U. Correll and E. M. Schenk, “Tardive dyskinesia and new antipsychotics,” Current Opinion in Psychiatry, vol. 21, no. 2, pp. 151–156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Seeman, “Atypical antipsychotics: mechanism of action,” Canadian Journal of Psychiatry, vol. 47, no. 1, pp. 27–38, 2002. View at Google Scholar · View at Scopus
  10. B. S. Wagh, B. P. Patil, M. S. Jain, S. S. Harak, and S. B. Wagh, “Synthesis and evaluation of antipsychotic activity of 11-(4-aryl-1-piperazinyl)-dibenz [b, f][1,4] oxazepines and their 8-chloro analogues,” Heterocyclic Communications, vol. 13, no. 2-3, pp. 165–172, 2007. View at Google Scholar · View at Scopus
  11. D. S. Robinson, “Clozapine agranulocytosis: mechanism of drug toxicity,” Primary Psychiatry, vol. 13, no. 3, pp. 27–29, 2006. View at Google Scholar · View at Scopus
  12. C. M. Beasley Jr., G. D. Tollefson, and P. V. Tran, “Efficacy of olanzapine: an overview of pivotal clinical trials,” Journal of Clinical Psychiatry, vol. 58, no. 10, pp. 7–12, 1997. View at Google Scholar · View at Scopus
  13. E. Stip, “Novel antipsychotics: Issues and controversies. Typicality of atypical antipsychotics,” Journal of Psychiatry and Neuroscience, vol. 25, no. 2, pp. 137–153, 2000. View at Google Scholar · View at Scopus
  14. B. Capuano, I. T. Crosby, E. J. Lloyd, and D. A. Taylor, “Synthesis and preliminary pharmacological evaluation of 4′-arylmethyl analogues of clozapine—I. The effect of aromatic substituents,” Australian Journal of Chemistry, vol. 55, no. 9, pp. 565–576, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Capuano, I. T. Crosby, E. J. Lloyd, A. Podloucka, and D. A. Taylor, “Synthesis and preliminary pharmacological evaluation of 4′-arylalkyl analogues of clozapine—II. Effect of the nature and length of the linker,” Australian Journal of Chemistry, vol. 56, no. 9, pp. 875–886, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Capuano, I. T. Crosby, E. J. Lloyd, J. E. Neve, and D. A. Taylor, “Aminimides as potential CNS acting agents—II. Design, synthesis, and receptor binding of 4′-arylalkyl aminimide analogues of clozapine as prospective novel antipsychotics,” Australian Journal of Chemistry, vol. 61, no. 1, pp. 5–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. “LigPrep, version 2.5,” Schrödinger, New York, NY, USA, 2011.
  18. G. Chang, W. C. Guida, and W. C. Still, “An internal coordinate Monte Carlo method for searching conformational space,” Journal of the American Chemical Society, vol. 111, no. 12, pp. 4379–4386, 1989. View at Google Scholar · View at Scopus
  19. “MacroModel, version 9.9,” Schrödinger, New York, NY, USA, 2011.
  20. E. Archer, B. Maigret, C. Escrieut, L. Pradayrol, and D. Fourmy, “Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors?” Trends in Pharmacological Sciences, vol. 24, no. 1, pp. 36–40, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. “Prime, version 3.0,” Schrödinger, New York, NY, USA, 2011.
  22. G. N. Ramachandran, C. Ramakrishnan, and V. Sasisekharan, “Stereochemistry of polypeptide chain configurations,” Journal of Molecular Biology, vol. 7, pp. 95–99, 1963. View at Google Scholar · View at Scopus
  23. “Glide, version 5.7,” Schrödinger, New York, NY, USA, 2011.
  24. G. S. Kabinoff, P. A. Toalson, H. K. Masur, H. C. McGuire, and D. P. Hay, “Metabolic Issues with Atypical Antipsychotics in Primary Care: dispelling the myths,” Journal of Clinical Psychiatry, vol. 5, no. 1, pp. 6–14, 2003. View at Google Scholar
  25. B. Eiermann, G. Engel, I. Johansson, U. M. Zanger, and L. Bertilsson, “The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine,” British Journal of Clinical Pharmacology, vol. 44, no. 5, pp. 439–446, 1997. View at Google Scholar · View at Scopus
  26. G. V. Bakken, I. Rudberg, H. Christensen, E. Molden, H. Refsum, and M. Hermann, “Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5,” Drug Metabolism and Disposition, vol. 37, no. 2, pp. 254–258, 2009. View at Publisher · View at Google Scholar · View at Scopus